SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
biotech firesales
An SI Board Since August 2001
Posts SubjectMarks Bans
3661 167 0
Emcee:  dalroi Type:  Moderated
Introduction Compact
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
3436Ardelyx (ARDX) off 35% or so on superficially successful P3 trial in IBS-C. Thetuck-5/12/2017
3435I'm just not trading the suckers, Tuck. And my positions are quite modest. scaram(o)uche-5/8/2017
3434KITE off 15% as it discloses a patient death due to neurotoxicity, a problem it tuck-5/8/2017
3433rxdx, quick back of envelope... market cap after offering will be ~ 340m, andscaram(o)uche-5/3/2017
3432rxdx... earnings "miss", competitor data coming at asco, and a secscaram(o)uche-5/3/2017
3431Hi RKRW, I was searching about robert duggan and I saw you mention him on this tmarkdevera92-5/3/2017
3430NewLink (NLNK), which has been a big run lately gives over 20% back on data fromtuck-4/4/2017
3429Corbus (CRBP) off 15% now on "positive" CF trial data. Positive data tuck-3/30/2017
3428Thanks for the pointer. Friday, wasn't paying attention. Not that I pay attscaram(o)uche-3/24/2017
3427Xenon (XENE), after running up ~25% in anticipation of acne drug results, splutstuck-3/24/2017
3426GNMX down 60% on ADHD failIRWIN JAMES FRANKEL-3/20/2017
3425PETX -23%, possibly on earnings newstnsaf-3/15/2017
3424PTCT off 16% pre market as Ataluren whiffs in cystic fibrosis. Cheers, Tuktuck-3/2/2017
3423CDTX - 41% failed trial. Hard day! I had a 20% allocation in charity contest. ArSteve Lokness-2/21/2017
3422MNTA -20% PFE has an issue with the fill and finish for the gCopaxone 40mg thatIRWIN JAMES FRANKEL-2/21/2017
3421p=0.07 for 0.35mg, Apollo 1, "respiratory safety burden". Entirety ofscaram(o)uche-2/21/2017
3420Trevena (TRVN) off 34% premarket. They needed a home run in P3 post op pain trtuck-2/21/2017
3419ARQL 20% "ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo today announced thnigel bates-2/17/2017
3418Good prediction, LOL.DewDiligence_on_SI-2/8/2017
3417EYES - down 27% today after huge move up yesterday. Not a surprise. I expect moRocky9-2/8/2017
3416OCRX - thrown into a volcanotnsaf-1/30/2017
3415CEMP - Now close to 60% decline. Arrrg! More liver issues...........Steve Lokness-12/29/2016
3414FDA puts clinical hold on Seattle Genetics' cancer drug after 4 deaths finanJulius Wong-12/27/2016
3413Ophthotech's stock plunges toward record low after drug trials miss primary Julius Wong-12/12/2016
3412SGEN AH price up ...on 175 shares???!!! My concern is not stock price, sgen or Miljenko Zuanic-11/30/2016
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News